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Plasma triglyceride levels are higher in nephrotic than in analbumin-
ernie rats despite a similar increase in hepatic triglyceride secretion. The
relative contributions of increased hepatic secretion of triglyceride (TO)
and decreased TG catabolism to hypertriglyceridemia in the nephrotic
syndrome, and their relationship to urinary protein loss and reduced
plasma colloid osmotic pressure (IT) remain unclear. We measured the
activity of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS),
two key enzymes of fatty acid synthesis in hepatic cytosol, in fed control
rats, in rats with congenital analbuminemia (NA) that are free of
proteinuria, and in rats with adriamycin-induced nephrotic syndrome
(ADR). Both NA and ADR rats had decreased IT (respectively 13.2 0.3
and 10.7 0.4 mm Hg vs. control rats 18.3 0.7 mm Hg, P < 0.05), but
only ADR rats had increased plasma TO (5.8 2.6 mmol/liter vs. 1.5
0.2 mmol/liter in both control and NA rats, P < 0.05), and were
proteinuric: 811 45 mg/day, P < 0.01 versus control and NA rats. Total
cytosolic ACC activity, expressed per g body weight, was increased in both
NA and ADR rats by 45% and 39%, respectively (P < 0.05). Total FAS
activity was increased by 65% and 115% in NA and ADR rats, respectively
(P < 0.05). Thus low r was consistently associated with an increase in total
ACC and FAS activities in the livers of fed rats. However, low IT was
consistently associated with an increase in plasma TG only in ADR rats.
Hepatic TG secretion rates, measured in vivo after blocking lipolysis with
Triton WR-1339 in fasting animals, were increased by 33% in both ADR
and NA rats as compared to controls (P < 0.05). Thus in the fasted state
low IT was associated with an increase in TG secretion rate. In fasted
control rats plasma TG levels were low (0.5 0.05 mmol/liter). Plasma
TG were increased in NA (2.1 2 mmol/liter; P < 0.05 vs. control), ADR
(3.4 0.5 mmol/liter; P < 0.05 vs. control and NA) and in NA rats with
ADR-induced proteinuria (4.6 1.5 mmol/liter; P < 0.05 vs. control and
NA). Since TG secretion rates and involved liver enzyme activities are
equally increased in both NA and ADR rats, whereas plasma TO
concentration is consistently higher in ADR than in NA rats, we suggest
that the severe hypertriglyceridemia in nephrotic rats is due to a combi-
nation of hypoproteinemia-linked increase in TO synthesis and a protein-
uria-linked impairment of TO catabolism.
Hypertriglyceridemia is present in severe nephrotic syndrome[1, 2] and triglyceride (TG) turnover rate was found to be
increased [3], notably in patients with fasted plasma TG levels
above 2.5 mmollliter (200 mgldl) [I• There is general agreement
Received for publication November 17, 1993
and in revised form September 19, 1994
Accepted for publication September 19, 1994
© 1995 by the International Society of Nephrology
that hepatic synthesis of fatty acids (FA) [5] is increased in
experimental models of the nephrotic syndrome, while removal of
TG-rich particles, chylomicrons [6] and very low density lipopro-
teins (VLDL) [7] is reduced. Both increased hepatic synthesis of
FA and secretion of TG as well as decreased TG catabolism
appear to contribute to the hypertriglyceridemia [3—7]. However,
the relative importance of these two mechanisms, and their
relationship to urinary protein loss, hypoalbuminemia and re-
duced plasma colloid osmotic pressure (ir) remain unclear. He-
patic cholesterol synthesis and secretion are presumed to be
stimulated by low ir or hypoalbuminemia [5, 8]. However, it is not
known whether hepatic FA synthesis and TG secretion, which
under physiological conditions are primarily controlled by food
intake [9], also respond positively to these stimuli.
Acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS)
are key enzymes in the synthesis of hepatic long-chain FA [9].
Data on ACC and FAS activity in ADR and NA rats have not
been reported previously. The activities of regulatory enzymes of
the hepatic and adipose fatty acid synthesis pathway are decreased
in the initial period after the induction of experimental nephrotic
syndrome by puromycin aminonucleoside (PAN) [10], probably
because of the toxic effect of this substance on RNA [11] and
hence on protein [10] synthesis. In a later stage the activities of
these enzymes in the liver recover and even increase above
baseline, but it is not clear to what extent this is secondary to
nephrosis or to the recovery of liver function after toxic insult. TG
secretion has also never been studied in vivo in ADR rats. The
rate of secretion of VLDL is increased in perfused livers from rats
with nephrotic syndrome induced by administration of PAN [12,
13]. TG secretion rates are also increased in vivo in rats with
PAN-induced nephrotic syndrome [14, 15]. However, as explained
above, it may be hazardous to draw conclusions about distur-
bances related to liver function solely from the PAN model.
We presently measured TG secretion rates in vivo as well as the
activity of ACC and FAS in hepatic cytosol obtained from control
Sprague-Dawley rats (control) and rats with either congenital
analbuminemia (NA) or Sprague-Dawley rats with adriamycin-
induced nephrotic syndrome (ADR). TG secretion rates were also
measured in NA rats with adriamycin-induced nephrotic syn-
drome (NA-ADR). Comparing these models enabled us to sepa-
rate the effects of hypoalbuminemia per se from those linked to
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other abnormalities in plasma that are the result of proteinuria or,
more specifically, loss of a liporegulatory substance [6J.
Methods
Animals
Male SD rats (N 53), weighing approximately 250 g, were
purchased from Harlan-Olac (UK). Male NA rats (N = 24),
weighing approximately 250 g, were from our own pathogen-free
colony (which was founded with animals donated by Dr. S.
Nagase, Tokyo, Japan). The SD rats were divided into two groups
at random. Twenty-six animals were injected into a tail vein with
adriamycin (Adriblastina RTUR, Farmitalia Carlo Erba S.A.,
Nivelles, Belgium) at a dose of 4 mg/kg (ADR), and the remaining
27 animals were not treated (CON). Five of the NA rats were also
injected with adriamycin (NA-ADR). The rats were housed
behind barriers in filter-top cages. Sentinel animals, which were
monitored regularly for infection by nematodes and pathogenic
bacteria, as well as antibodies to a large number of rodent viral
pathogens (ICIAS, Nijmegen, the Netherlands), were consis-
tently negative throughout the course of the experiment. The rats
were provided with a semi-synthetic diet (Hope Farms, Woerden,
The Netherlands) containing 20% casein-protein, 10% corn
starch, 5% cellulose, 53% glucose monohydrate, and 5% soybean
oil (by weight). The remaining 7% consisted of salts, vitamins, and
trace elements. Water and food were available ad libitum unless
otherwise specified. The protocol was approved by the Utrecht
University Board for study in experimental animals.
The rats were divided into three groups, one non-fasting group
for measuring hepatic enzyme activities and plasma (apo)lipopro-
tein composition, one fasting group for measurement of TG
secretion rates (see below), and one group in which TG secretion
rates were measured in the fed state. In the latter group blood was
also sampled in the fasted state one week prior to the final
measurements in the fed state to allow paired comparison. Prior
to terminal experiments we measured proteinuria and kidney
function to ensure that the degree of proteinuria and decrease in
kidney function were equal in the ADR subsets, and to exclude
significant proteinuria in NA and control rats.
Renal function
Urine was collected after seven weeks in all rats injected with
adriamycin as well as in 17 untreated controls and 13 NA rats for
determination of the excretion of creatinine and protein. The rats
were placed in macrolon metabolism cages for 24 hours with free
access to food and water. The rats were not used for subsequent
measurements in the first two days after being removed from the
metabolism cages. Creatinine clearances were calculated using the
plasma creatinine levels determined in terminal blood samples,
and corrected for body weight.
Triglyceride secretion rate
Triton WR-1339 is a nonionic detergent that blocks the removal
of TG from the circulation, causing a linear increase of plasma TG
concentration. The rate of this increase is a measure of the total
TG secretion rate [16]. TO secretion rate was determined in 10
controls, 6 NA, 9 ADR and 5 NA-ADR rats under pentobarbital
anesthesia (60 mg/kg) after an overnight fast, using Triton WR-
1339 (Sigma Chemical, St. Louis, MO, USA) at a dose of 600
mg/kg, injected into a tail vein. TO secretion rates were also
determined in 7 controls, 6 NA and 5 ADR rats in the fed state.
Blood was sampled from the tail artery for TG analysis just before
injection of Triton (t 0) and at 30, 60 and 90 minutes
post-injection. The TO secretion rate was calculated as the
difference between the calculated 60-minute value obtained from
linear regression using the four measured samples and the
measured t 0 value multiplied by plasma volume [17]. Plasma
volume (ml) was assumed to be 4% of body weight [18, 19].
Hepatic enzyme activities
Ten control, 7 NA and 9 ADR rats were exsanguinated in the
fed state by puncture of the abdominal aorta under pentobarbital
anesthesia. The blood sample was lost in one nephrotic animal.
Subsequently the liver was quickly removed, weighed and a small
piece of liver was immediately homogenized (25% homogenate,
wt!vol) with a loose-fitting Dounce homogenizer (5 strokes) in
ice-cold medium containing 50 mrvi Hepes (pH 7.5), 0.25 M
mannitol, 4.0 m citrate, 6.16 mivi EDTA, and 5.0 mrvi 2-mercap-
toethanol. An additional small volume of a concentrated citrate!
EDTA solution was added to bring these compounds to final
concentrations of 4.0 and 6.16 m, respectively. The crude
homogenate was centrifuged at 12,000 g for two minutes, and
samples of the resulting supernatant were frozen in liquid nitro-
gen and stored at —70°C for subsequent enzyme assays.
Measurement of acetyl-CoA carboxylase (ACC) activity was
performed as described previously [20]. Briefly, in this assay the
malonyl-CoA forming carboxylase reaction is coupled to the fatty
acid synthase (FAS) reaction. The activity is determined by
measuring the incorporation of [1 -'4C]acetyl-CoA into fatty acids.
This prevents interference of malonyl-CoA decarboxylase and
pyruvate carboxylase activities in crude homogenates and inhibi-
tion of ACC by malonyl-CoA [21]. Supernatant, obtained by
centrifugation at 12,000 g and diluted in homogenization buffer,
was preincubated for 30 minutes at 37°C. Assays were started by
the adding 100 il of preheated assay mixture (37°C) to 100 d of
the biological sample (0.37 to 0.50 mg protein). Reactions were
stopped after one minute by addition of 100 il 10 M NaOH. The
total incubation mixture for the assay contained 75 mM Hepes (pH
7.5), 125 mrvi mannitol, 2.5 mri 2-mercaptoethanol, 3.1 mMEDTA,
4.0 mM citrate, 5.6 m'vi MgCl2, 2.0 mi ATP, 20 mM KHCO3,
0.93% (wt!vol) bovine serum albumin (charcoal treated and
dialyzed), 0.44 mvt dithioerythritol, 0.5 mivi NADPH, 0.062 mM
butyryl-CoA, 0.062 mrvi [1-14C]acetyl-CoA (4 Ci/mol), and 3.2 mU
FAS. The rest of this procedure was performed exactly as
described [21]. Intra-assay variability for ACC activity was 4%.
FAS activity was determined by measuring the incorporation of
[1-'4C]acetyl-C0A into fatty acids in the presence of malonyl-
CoA. Supernatant, obtained by centrifugation at 12,000 g, and
diluted in homogenization buffer (plus 3 mrvi dithiothreitol), was
prewarmed for five minutes at 37°C. Assays were started by the
adding 100 s1 of preheated assay mixture (37°C) to 100 1.d of the
biological sample (0.075 to 0.10 mg protein). Assays were stopped
after five minutes by adding 100 1d 10 M NaOH. The total
incubation mixture contained 75 mrvi Hepes (pH 7,5), 125 mrvi
mannitol, 2.0 mrvi citrate, 4.16 mrvi EDTA, 37.5 mrvi NaCI, 1.5 mM
dithiothreitol, 2.5 m 2-mercaptoethanol, 0.93% (wt!vol) bovine
serum albumin (charcoal treated and dialyzed), 0.5 mivi NADPH,
0.062 mM [1-14C]acetyl-C0A (4 Ci!mol) and 0.195 mi malonyl-
CoA. Fatty acids were extracted and quantified as described [21].
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Intra-assay variability for FAS activity was 2%. Lactate dehydro-
genase (LDH) was determined to monitor possible effects on
constitutive hepatic enzymes [22]. Cytosolic protein was deter-
mined by the Lowry method using bovine serum albumin as
standard. Cytosolic protein concentration was similar in all
groups.
Lipoprotein isolation by density-gradient ultracentrifugation
In non-fasting rats (5 control, 5 NA and 6 ADR) plasma
lipoproteins were separated by density-gradient ultracentrifuga-
tion [23] into seven fractions (chylomicrons and VLDL, d < 1.006
g/ml; intermediate density lipoprotein, IDL, d 1.006 to 1,019 g/ml;
low density lipoprotein, LDL1, d 1.019 to 1.04 g!ml and LDL2,
1.04 to 1.063 g/ml; high density lipoprotein HDL2, d 1.063 to 1.125
g/ml and HDL3, d 1.125 to 1.21 g/ml and an infranatant with a
d> 1.21 g/ml). The subdivision of LDL into LDL1 and LDL2 was
performed to separate the apo B containing lipoproteins from the
other particles present in the total LDL density range of 1.019 to
1.063 glml [24]. Lipoprotein cholesterol was measured as de-
scribed above.
Chemical analyses
Plasma and urinary protein were determined by the Bradford
method. Colloid osmotic pressure (ir) was measured using a strain
gauge microoncometer. Plasma and urinary creatinine were de-
termined colorimetrically (Sigma). Enzymatic methods were used
for the determination of total plasma cholesterol (TC) and TG.
The kits for these enzymatic assays were obtained from Boehr-
inger GmbH (Mannheim, Germany). Plasma concentrations of
apo A-I and apo E were measured by electroimmunoassay [25].
Plasma apo B was determined by radial immunodiffusion, using a
specific antiserum raised in rabbits against purified rat LDL [24].
Calculations and statistical analysis
Plasma TG was log-normalized as the distribution was skewed.
Values were subjected to one-way or two-way analysis of variance
where appropriate. If a variance ratio (F) reached statistical
significance (P < 0.05), the differences between the means were
analyzed by t-test using Bonferroni protection [26]. Results are
expressed as arithmetic means with their standard errors (sEM).
Results
Lipoprotein composition and hepatic enzyme activities in
non-fasting rats
Significant proteinuria was present in the ADR rats, compared
to the control and NA rats (Table 1). Creatinine clearance was
decreased by 40%. Plasma ir and total protein concentration were
reduced in both NA and ADR rats as compared to control rats.
Plasma r was significantly lower in ADR than in NA rats (Table
1), despite the similar total protein concentration. This discrep-
ancy was most likely due to the predominance of the large
molecular weight proteins in nephrotic plasma [27], whereas the
analbuminemic plasma is characterized by an increase in both
small and large non-albumin proteins [28]. Hyperlipidemia was
more severe in ADR than in NA rats. This was evident from both
cholesterol and apolipoprotein concentrations. Plasma VLDL,
IDL, LDL1, LDL2 and HDL2 cholesterol levels were markedly
increased in ADR rats, whereas the increases in LDL1, LDL2 and
Table 1. Twenty-four-hour urine analysis, plasma colloid osmotic
pressure (ir), total protein, cholesterol and apolipoprotein (apo)
concentrations in non-fasted control rats (CON), analbuminemic rats
(NA), and rats with adriamycin-induced nephrotic syndrome (ADR)
CON NA ADR
N 10 7 8
Proteinuria mg/day 30 4 14 2 811 45
Creatinine clearance
pi/min •100 gbody wt
r mm Hg
434 48
18.3 0.7
398 26
13.2 Q3 259 12at,10.7 0•4ah
Total protein g/liter
Cholesterol mmol/liter
61.9 1.8
2.3 0.1
53.1 1.Oa
5.3 0.3a
54.6 1.O'
14.0 1.8'
apo A-i mg/dl
apo BA.U.
apo E mg/dl
33 1
88 10
16.3 1.3
94 3
168 8
20.0 1.0
201 17'
285 35ab
43.7 l.2'
Data are mean SEM. AU. is arbitrary units.
aP < 0.05 vs. CON
bP < 0.05 vs. NA
CN = 9
HDL2 in NA rats were mild (Fig. 1). HDL3 cholesterol was
increased about twofold in both NA and ADR rats.
Plasma triglyceride concentrations were not elevated in NA rats
and the mean value was increased in ADR rats (Table 2). Note
that plasma triglyceride distribution was skewed in the ADR rats:
median 1.85 mmol!liter, range 1.4 to 21.3 mmol/liter. Data
pertaining to hepatic FA synthesis are also listed in Table 2. Final
body weight was lower in ADR rats, because growth rates
decrease after adriamycin administration at or above a dose of 4
mg/kg body weight [29—31]. Liver weight, in proportion to body
weight, was markedly increased in ADR rats. Hypertrophy of the
liver is characteristic of all experimental models of the nephrotic
syndrome [5, 32], with the exception of PAN-induced nephrosis
[5]. Our interest was primarily directed towards the contribution
of the liver to circulating lipid levels; therefore we normalized
enzyme activities for differences in liver weight and body weight.
It should be noted that this maximized the difference between the
ADR and the other two groups. Enzyme activities in the controls
varied considerably between assay runs. Hence, we chose to
normalize enzyme activities for the values found in the control
animals measured in the same run. Activity of LDH/g body weight
was similar in all three groups. Total cytosolic ACC activity,
expressed per whole liver per g body weight, was elevated to a
similar extent in both NA and ADR rats. Total cytosolic FAS
activity was increased by 65% and 115%, in NA and ADR rats,
respectively. The increases in FAS activity were not significantly
different between NA and ADR rats.
Triglyceride secretion rates in fasting rats
Proteinuria, kidney function, plasma r, total protein and cho-
lesterol were similar in fasted ADR rats when compared to these
values in their non-fasted counterparts (cf. Table 1). Proteinuria
was varied between 117 and 496 mg/day in the NA-ADR rats, and
the mean value was lower than in the ADR rats (P < 0.05), as has
been reported previously [331. Creatinine clearance was less
impaired in the NA-ADR rats, but total protein, cholesterol and
r were similar to the values found in the ADR rats. Plasma TG
concentrations were highest in the NA-ADR rats, and again
higher in ADR than in NA rats, but, in contrast to the situation in
the non-fasted animals, NA rats also showed a significant increase
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CON NA ADR
N 10 7 9
Triglycerides mmol/ 1.49 0.23 1.53 0.19 5.81 2,62at,c
liter
Bodywtg 444±28 497±28 259÷11ab
Liver weight g/100 g 3.00 0,12 3.20 0.05 4.86 0.25'
body wt
LI-I activity UIg 100.0 3.6 116.9 8.6 110.1 10.2
body; % of CON
ACC activity 100.0 5.7 145.1 11.2 138.7 15.1
nmol/min 'g body
wt; % of CON
FAS activity 100.0 5.2 164.7 18.6a 215.4 31.2a
nmol/min g body
wt; % of CON
Enzyme activities, shown as a percentage of mean control levels, are
expressed as total activity (per g body wt). Data are mean SEM.
ap < 0.05 vs. CON
'P <0.05 vs. NA
= 8
as compared to the control rats (Table 3). This was mainly due to
the much lower plasma TG concentration in fasted controls as
compared to fed controls (0.51 0.05 vs. 1.49 0.23 mmol/liter;
P < 0.001; unpaired t test). After Triton WR-1339 treatment, the
TO secretion rates calculated per 100 g body weight were
increased by 33% in both ADR and NA rats (P < 0.05), whereas
in NAR-ADR the 15% increase did not reach significance (Table
3). Thus superimposing proteinuria on low r in the NAR caused
a significant increase in plasma TO concentration without any
change in triglyceride secretion rate.
Direct evaluation of the effect of food intake on plasma TO
levels and TG secretion rates was studied in an additional cohort
of NA and ADR rats to elucidate whether the primary stimulus
for TO secretion by the liver, namely feeding, could be modulated
Table 3. Body weight, 24-hour urine analysis and fasted plasma colloid
osmotic pressure (ir), total protein, cholesterol and plasma triglyceride
concentrations and triglyceride secretion rate (TGSR) in control rats
(CON), analbuminemic rats (NA) and CON and NA rats with
adriamycin-induced nephrotic syndrome (ADR and NA-ADR,
respectively)
CON NA ADR NA-ADR
N 10 6 9 5
Body weight g 327 14 241 8 253 ioa 281 6at,
Proteinuria ND ND 828 68 300 77
mg/day
GFR ND ND 263 6 418 5QC
pJ/min 100
ir body wt
iT mm Hg 21.0 0.5 13.4 Q•4 11.9 0.9 11.1 02ah
Total protein 59.3 1.4 50.3 i.r' 52.8 IT 49.4 L1
giliter
Cholesterol 1.9 0.1 4.6 0.2 15.5 14ab 11.2 2.7'"
mmol/liter
Triglycerides 0.51 0.05 2.13 0.16a 3.38 0.47°' 4.56 1.50'
mmol/liter
TGSR 52 3
nmol/min . 100
69 6 69 5 60 2
g body wt
by a decrease in r(Table 4). Values after 24 hours of fasting were
obtained one week prior to the final values measured in the
non-fasted state. Proteinuria was comparable to that seen in the
other cohorts. Food intake was similar in the NA and control rats,
but considerably reduced in ADR rats. As a result control and NA
rats gained weight during the week between assay of fasted and
fed parameters, whereas the ADR rats remained at more or less
constant body weight. This can be appreciated by comparing the
values observed in the fasted and non-fasted state. The severity of
nephrosis also progressed in the final week as can be appreciated
by the fall in iT and total protein (both P < 0.05). Non-fasting as
compared to fasting increased mean plasma TG levels in all
groups. The increase was significant in the NA and ADR rats.
Importantly, the TO levels in the NA rats in this cohort were
6-.
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* Fig. 1. Plasma lipoprotein cholesterol
concentrations in non-fasted control rats (CON,
closed bars), analbuminemic rats (NA, open
bars) and rats with adriamycin-induced nephrotic
syndrome (ADR, hatched bars). Data are meanLDL2 HDL2 HDL3 SEM. "P < 0.05 vs. CON; #P < 0.05 vs. NA.
Table 2. Plasma triglyceride concentrations, liver weight and hepatic
cytosolic activity of lactate dehydrogenase (LDH), acetyl CoA
carboxcylase (ACC) and FA synthase (FAS) in non-fasted control rats
(CON), anabuminemic rats (NA) and rats with adriamycin-induced
nephrotic syndrome (ADR)
ND is not determined. Data are mean SEM.
a P < 0.05 vs. CONbP < 0.05 vs. NA
cp < 0.05 vs. ADR
Triglyceride levels compared in fasting and non-fasting rats
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Table 4. Twenty-four-hour urine protein, food intake, and paired
measurements of fasted and non-fasted plasma colloid osmotic pressure
(i'-), total protein, cholesterol and triglyceride concentrations, as well as
non-fasted triglyceride secretion rate (TGSR) in control rats (CON),
analbuminemic rats (NA) and rats with adriamycin-induced nephrotic
syndrome (ADR)
CON NA ADR
N
Proteinuria mg/day
Food intake g/100 g body
wt day
732 2
5.15 0.06
634 5
5.64 0.14
8
831 51ab
3.33 026ab
Fasted
Body weight g
rmm Hg
Total protein g/liter
Cholesterol mmol/liter
Triglycerides mmol/liter
244 3
21.0 0.3
60.7 1.5
2.45 0.16
0.79 0.09
228 4
13.3 0.9a
49.0 0.6°
4.93 0.14°
1.25 0.07a
287 19ab
14.1 0.7°
54.0 1.0°'
10.3 11ab
3.41
Non-fasted
Body weight g
irmm Hg
Total protein g/liter
Cholesterol mmol/liter
Triglycerides mmol/liter
TGSR nmol/min . bOg
body wt
284 5°
18.9 0.3
55.7 0.9°
2.49 0.17
0.99 0.1295 6
276 5°
14.5 0.3°
51.7 0.8°
6.37 0.11°°
3.02 0.50°°
121 12
285 22ab
11.8 05abc
49.4 0.9°'°
12.3 13ab
7.49 2.11°'°
98 14
Data are mean SEM.
aP < 0.05 vs. CON
hP < 0.05 vs. NA
P < 0.05 vs. fasted
significantly higher than in the controls, but significantly lower
than in the ADR rats in both the fasted and non-fasted condition.
TG secretion rates were much higher in the non-fasted state than
in the fasted state (cf. Tables 3 and 4). No significant differences
were observed in the non-fasted state, although the absolute
difference between the NA and controls exceeded that observed in
the fasting rats.
Discussion
The pathogenesis of hypertriglyceridemia in the nephrotic
syndrome was studied in three rat models with low plasma protein
and r: NA, ADR and NA-ADR rats. Mean plasma TG levels in
the fasted state were increased in all three groups. In the
non-fasted state the TG levels were also consistently increased in
the ADR rats, but this increase was inconsistent in NA rats. Both
NA and ADR rats demonstrated similar increases in total hepatic
activity of ACC and FAS distinct from minor changes in activity of
the constitutive enzyme, LDH. In addition, an identical mean
increase in hepatic TG secretion rate was observed in the fasted
state. Proteinuria induced by ADR in NA rats caused a further
increase in TG levels without an increase in TG secretion rates.
The significantly higher plasma TG concentration observed in
ADR and NA-ADR rats as compared to NA rats, despite these
similarities at key steps in the secretory pathway, suggests a
significant impairment in TG clearance in models where reduced
r is accompanied by proteinuria. A similar conclusion was drawn
by Furukawa et al [34], who observed a tenfold increase in plasma
TG levels in the presence of only a 20% increase in TG secretion
rates in rats with PAN-induced nephrosis.
ACC and FAS are key enzymes in the synthesis of hepatic
long-chain FA [9]. Hepatic FA synthesis and TG secretion are
controlled by short-term and long-term regulation. Short-term
regulation is primarily determined by food intake. Hepatic FA
synthesis [35] and TG output [36] are decreased by fasting. The
fact that the increase in hepatic secretion rate of TG was observed
in fasting rats and that increases of total hepatic ACC and FAS
activities were observed in fed rats suggests a constitutive increase
in hepatic TG secretion both in the fed and fasted state in NA and
ADR rats. Interpretation of the TG secretion rates measured in
the fed state is ambiguous because quantitative information on
the contribution of the gut is not available. Nevertheless, the
results suggest that in NA, ADR and NA-ADR rats hepatic FA
synthesis is stimulated to a similar extent, possibly by a common
factor. The nature of this factor is unknown. Elevated TG
secretion in NA rats could not be suppressed by infusions of
albumin or dextran [37].
The higher triglyceride levels in the proteinuric rats are likely to
be related to impaired TG catabolism. TG catabolism is probably
more rapid in NA than in ADR or NA-ADR rats. Indeed, a
markedly delayed clearance of chylomicrons and VLDL has been
observed in fasted control and NAR rats with nephrotic syndrome
induced by passive Heymann nephritis, whereas the chylomicron
and VLDL clearances were normal in fasted non-proteinuric NA
rats [38]. Delays in chylomicron and VLDL clearances have also
been observed in fasted rats with PAN-induced nephrotic syn-
drome [7, 39]. A similar delayed clearance of TG-rich particles is
probably present in the rats with ADR-induced nephrotic syn-
drome used in the present study.
In the present experiments we did not investigate whether the
increased activity of ACC and FAS in NA and ADR rats actually
results in increased hepatic FA production in vivo. However, in a
previous study we observed a 35% increase in the incorporation of
3H2O into hepatic FA in NA rats [40]. There are also reports of
a twofold increase in the incorporation of 3H20 into hepatic FA
in rats with PAN-induced nephrotic syndrome [41, 42]. Thus, we
presume that the increased ACC and FAS activities observed in
the present experiments actually resulted in elevated FA synthesis
in vivo.
The cardinal difference between the models of low r used in
this study, is the presence of proteinuria in ADR and NA-ADR
rats and its absence in NA rats. It is expedient to hypothesize that
this difference is linked to the difference in TG catabolism. It has
been postulated that a factor needed to activate lipolysis is lost in
the urine. Neither albumin loss as such nor the quantitative loss of
protein appear to be responsible for the putative defect in TG
catabolism as TG levels were even higher in NA-ADR rats than in
ADR rats. Thus inhibition of lipoprotein lipase by accumulation
of free fatty acids and monoglycerides secondary to deficiency of
the fatty acid receptor albumin [43] can be ruled out. A more
likely candidate is low molecular weight heparan sulphate that was
isolated from urine of patients with the nephrotic syndrome [44].
Heparan sulphate increased the clearance of chylomicrons when
administered to nephrotic rats, and increased lipolysis in vitro [6,
44]. Besides the well-documented defect in initial clearance of
TG-rich particles, other lipoprotein clearance defects appear to
be present in the nephrotic syndrome. Decreased LDL receptor
function has been postulated based on turnover studies in ne-
phrotic patients [45]. In rats with nephrotic syndrome induced by
passive Heymann nephritis, defects in the peripheral uptake of
chylomicrons and in the hepatic uptake of remnants have been
identified [46]. The latter finding is supported by the marked
increase of plasma apo E and of the apo B containing lipoproteins
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IDL and LDL1 observed in ADR but not in NA rats in the present
study. In the rat, an animal devoid of plasma cholesterol ester
transfer protein activity [47], the cholesterol esters in these
particles are primarily derived from VLDL and to a lesser extent
from chylomicrons. Thus, it is likely that important differences in
VLDL, IDL and LDL levels between NA rats and rats with the NS
are mainly due to differences in lipoprotein catabolism.
In summary, in rats with low plasma protein and r, with (ADR
rats) or without (NA rats) proteinuria, hepatic TO production
appears to be increased. In both conditions, activities of FAS and
ACC and TG secretion rates are increased. However, plasma TG
levels are higher in ADR than in NA rats, indicating that a
catabolic defect, that may somehow be linked to proteinuria, also
plays an important role in the pathogenesis of hypertriglyceri-
demia in the nephrotic syndrome.
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